REG - LungLife AI, INC - Block listing Interim Review

LungLife AIAnnouncement

15/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241115:nRSO7676La&default-theme=true

RNS Number : 7676L  LungLife AI, INC  15 November 2024

LungLife AI, Inc.

(the "Company" or "LungLife")

 

Block Listing Six Monthly Return

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung
cancer, makes the following six monthly update on its block listing pursuant
to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:

 

 Name of applicant:                                                                LungLife AI, Inc.
 Name of scheme:                                                                   1.    2010 Stock Incentive Plan

                                                                                   2.    2020 Stock Incentive Plan

                                                                                   3.    2021 Omnibus Long-Term Incentive Plan
 Number and class of securities originally admitted:                               1,356,139 common shares of US $0.0001 each
 Date of admission:                                                                15 November 2021
 Period of return:                        From:                                    15 May 2024       To:               15 November 2024
 Balance of unallotted securities under scheme(s) from previous return:            1.    475,583

                                                                                   2.    201,374

                                                                                   3.    673,990
 Plus: The amount by which the block scheme(s) has been increased since the        1.    NIL
 date of the last return (if any increase has been applied for):

                                                                                   2.    NIL

                                                                                   3.    NIL
 Less: Number of securities issued/allotted under scheme(s) during period (see     1.    NIL
 LR3.5.7G):

                                                                                   2.    NIL

                                                                                   3.    NIL
 Equals: Balance under scheme(s) not yet issued/allotted at end of period:         1.    475,583

                                                                                   2.    201,374

                                                                                   3.    673,990
 Total number of securities in issue at the end of the period                      30,658,603

 

 Name of contact:              David Anderson, Chief Financial Officer
 Telephone number of contact:  +44 (0)20 7933 8780

 

 

For further information please contact:

 

 LungLife AI, Inc.                                   www.lunglifeai.com (https://www.lunglifeai.com/)
 Paul Pagano, CEO                                    via investors@lunglifeai.com
 David Anderson, CFO

 Investec Bank plc (Nominated Adviser & Broker)      Tel: +44 (0)20 7597 5970
 Virginia Bull / Lydia Zychowska / Sara Wallace

 Goodbody (Joint Broker)                             Tel: +44 (0)20 3841 6202
 Tom Nicholson / Cameron Duncan

 

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a
significant impact in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's LungLB® test
is designed to deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit www.lunglifeai.com
(http://www.lunglifeai.com)

 

Our Purpose is to be a driving force in the early detection to lung cancer.
And our Vision is to invert the 20:80 ratio such that in years to come at
least 80% of lung cancer is detected early.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRFLFIRLTLLLIS